RU2017123283A - Партнеры по слиянию для получения пептидов - Google Patents
Партнеры по слиянию для получения пептидов Download PDFInfo
- Publication number
- RU2017123283A RU2017123283A RU2017123283A RU2017123283A RU2017123283A RU 2017123283 A RU2017123283 A RU 2017123283A RU 2017123283 A RU2017123283 A RU 2017123283A RU 2017123283 A RU2017123283 A RU 2017123283A RU 2017123283 A RU2017123283 A RU 2017123283A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- protein
- recombinant fusion
- fusion protein
- polypeptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 26
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 16
- 241000589540 Pseudomonas fluorescens Species 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 10
- 230000004927 fusion Effects 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 108010081589 Becaplermin Proteins 0.000 claims 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 108010032976 Enfuvirtide Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108010011459 Exenatide Proteins 0.000 claims 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- -1 N-met-GCSF Proteins 0.000 claims 2
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims 2
- 108010076181 Proinsulin Proteins 0.000 claims 2
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 claims 2
- 229960004787 becaplermin Drugs 0.000 claims 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims 2
- 229960002062 enfuvirtide Drugs 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 239000004026 insulin derivative Substances 0.000 claims 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 2
- 229960001267 nesiritide Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229960003611 pramlintide Drugs 0.000 claims 2
- 108010029667 pramlintide Proteins 0.000 claims 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 2
- 108010073046 teduglutide Proteins 0.000 claims 2
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 claims 2
- 229960002444 teduglutide Drugs 0.000 claims 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 101100192865 Drosophila melanogaster GlyP gene Proteins 0.000 claims 1
- 108010013369 Enteropeptidase Proteins 0.000 claims 1
- 102100029727 Enteropeptidase Human genes 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 102000004961 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
- 108010057186 Insulin Glargine Proteins 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 claims 1
- 108010006519 Molecular Chaperones Proteins 0.000 claims 1
- 101710177166 Phosphoprotein Proteins 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960004717 insulin aspart Drugs 0.000 claims 1
- 229960003948 insulin detemir Drugs 0.000 claims 1
- 229960002869 insulin glargine Drugs 0.000 claims 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 claims 1
- 229960002811 ziconotide Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21009—Enteropeptidase (3.4.21.9), i.e. enterokinase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086119P | 2014-12-01 | 2014-12-01 | |
| US62/086,119 | 2014-12-01 | ||
| PCT/US2015/063027 WO2016089782A1 (en) | 2014-12-01 | 2015-11-30 | Fusion partners for peptide production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017123283A true RU2017123283A (ru) | 2019-01-09 |
Family
ID=56092296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017123283A RU2017123283A (ru) | 2014-12-01 | 2015-11-30 | Партнеры по слиянию для получения пептидов |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10118956B2 (https=) |
| EP (1) | EP3227455B1 (https=) |
| JP (2) | JP6817939B2 (https=) |
| KR (1) | KR102353262B1 (https=) |
| CN (2) | CN107532190B (https=) |
| AR (1) | AR102865A1 (https=) |
| AU (1) | AU2015355242B2 (https=) |
| CA (1) | CA2966358C (https=) |
| DK (1) | DK3227455T3 (https=) |
| ES (1) | ES2952405T3 (https=) |
| MX (1) | MX386884B (https=) |
| NZ (1) | NZ732400A (https=) |
| RU (1) | RU2017123283A (https=) |
| SG (1) | SG11201704362VA (https=) |
| TW (1) | TWI702289B (https=) |
| WO (1) | WO2016089782A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6817939B2 (ja) | 2014-12-01 | 2021-01-20 | フェネックス インク． | ペプチド産生のための融合パートナー |
| US9798758B2 (en) | 2015-05-15 | 2017-10-24 | Foogal Incorporated | Food freshness notification from personal food inventory |
| JP7784804B2 (ja) | 2017-10-27 | 2025-12-12 | フェネックス インク． | 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法 |
| WO2019083794A1 (en) | 2017-10-27 | 2019-05-02 | Pfenex Inc. | PROCESS FOR PRODUCING EAR ASPARAGINASE. RECOMBINED COLI |
| US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
| CN108191981B (zh) * | 2018-02-06 | 2020-11-03 | 美药星（南京）制药有限公司 | 一种利拉鲁肽中间体多肽的制备方法 |
| KR102009709B1 (ko) * | 2018-02-14 | 2019-08-12 | 주식회사 펩진 | 융합 폴리펩타이드를 이용하여 인간 부갑상선 호르몬 1-84를 생산하는 방법 |
| KR102017542B1 (ko) * | 2018-02-14 | 2019-09-03 | 주식회사 펩진 | 융합 폴리펩타이드를 이용하여 글루카곤 유사 펩타이드-2 또는 이의 유사체를 생산하는 방법 |
| KR102017540B1 (ko) * | 2018-02-14 | 2019-09-03 | 주식회사 펩진 | 융합 폴리펩타이드를 이용하여 글루카곤 유사 펩타이드-1 또는 이의 유사체를 생산하는 방법 |
| CN108977423A (zh) * | 2018-08-17 | 2018-12-11 | 集美大学 | 一种从猪肺中分离提纯血管紧张素转化酶的方法 |
| KR102011291B1 (ko) * | 2018-12-05 | 2019-10-21 | 주식회사 펩진 | 신규한 융합 폴리펩타이드 및 이를 이용하여 인간 부갑상선 호르몬 1-34를 생산하는 방법 |
| US11364223B2 (en) | 2018-12-13 | 2022-06-21 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
| CN110305223B (zh) * | 2019-06-26 | 2022-05-13 | 重庆派金生物科技有限公司 | 重组串联融合蛋白制备目标多肽的方法 |
| KR20210010368A (ko) * | 2019-07-19 | 2021-01-27 | 주식회사 펩진 | 글루카곤 유사 펩타이드-2 또는 이의 유사체 생산용 융합태그 |
| KR20210010367A (ko) * | 2019-07-19 | 2021-01-27 | 주식회사 펩진 | 인간부갑상선호르몬1-34 생산용 융합태그 |
| KR20210010366A (ko) * | 2019-07-19 | 2021-01-27 | 주식회사 펩진 | 글루카곤 유사 펩타이드-1 또는 이의 유사체 생산용 융합태그 |
| WO2021091304A1 (ko) * | 2019-11-08 | 2021-05-14 | 한국해양과학기술원 | 신규한 인간 상피세포성장인자-tf 융합 단백질 및 이의 용도 |
| CN113773400B (zh) * | 2020-06-09 | 2023-08-18 | 宁波鲲鹏生物科技有限公司 | 一种门冬胰岛素衍生物及其应用 |
| WO2022016118A2 (en) * | 2020-07-17 | 2022-01-20 | Cb Therapeutics, Inc. | Prenyltransferase enzymes |
| CN113151296B (zh) * | 2021-03-22 | 2022-09-13 | 云南中烟工业有限责任公司 | 一种烟草热激蛋白相关的基因及其应用 |
| CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
| CN113025599B (zh) * | 2021-04-02 | 2023-09-12 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 |
| KR20240021234A (ko) * | 2021-06-10 | 2024-02-16 | 펠리칸 테크놀로지 홀딩스, 인크. | 재조합 단백질 발현을 위한 박테리아 숙주 |
| EP4380955A1 (en) * | 2021-08-06 | 2024-06-12 | Roche Diagnostics GmbH | Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification |
| WO2023049631A2 (en) * | 2021-09-09 | 2023-03-30 | Northwestern University | Cell-free methods and compositions comprising tagless therapeutic hormones |
| CN114350587B (zh) * | 2022-01-24 | 2023-10-31 | 修实生物医药(南通)有限公司 | 一种基因重组串联表达利那洛肽的工程菌 |
| CN115109766A (zh) * | 2022-02-14 | 2022-09-27 | 上海理工大学 | 一种耐高温金属蛋白酶及其编码基因和应用 |
| WO2024035782A1 (en) * | 2022-08-10 | 2024-02-15 | Aav Gene Therapeutics, Inc. | Aav-mediated intramuscular delivery of insulin |
| WO2025081111A1 (en) * | 2023-10-12 | 2025-04-17 | The University Of Chicago | Methods and compositions for characterizing rna-binding protein binding sites by in-situ reverse transcription-based sequencing |
| CN121405791A (zh) * | 2025-12-26 | 2026-01-27 | 中国极地研究中心(中国极地研究所) | 一种重组胶原蛋白三螺旋折叠与稳定化方法 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769326A (en) | 1980-02-29 | 1988-09-06 | The Regents Of The University Of California | Expression linkers |
| US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| US4755465A (en) | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| US5281532A (en) | 1983-07-27 | 1994-01-25 | Mycogen Corporation | Pseudomas hosts transformed with bacillus endotoxin genes |
| US4695455A (en) | 1985-01-22 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of pesticides produced by expression of heterologous genes |
| US4695462A (en) | 1985-06-28 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of biological pesticides |
| GB8517071D0 (en) | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5128130A (en) | 1988-01-22 | 1992-07-07 | Mycogen Corporation | Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens |
| US5055294A (en) | 1988-03-03 | 1991-10-08 | Mycogen Corporation | Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens |
| US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
| US7150974B1 (en) | 1991-04-05 | 2006-12-19 | The General Hospital Corporation | Parathyroid hormone receptor binding method |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| CA2125467C (en) | 1993-07-06 | 2001-02-06 | Heinz Dobeli | Process for producing hydrophobic polypeptides, proteins or peptides |
| US5935824A (en) | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| CA2198966C (en) | 1996-03-04 | 2011-06-21 | Yuji Suzuki | Method for cleaving chimeric protein using processing enzyme |
| JPH1175879A (ja) * | 1997-07-08 | 1999-03-23 | Toyota Central Res & Dev Lab Inc | プロテインジスルフィドイソメラーゼを含有する融合タンパク質をコードするｄｎａ |
| US5989868A (en) | 1997-09-12 | 1999-11-23 | The Board Of Regents Of The University Of Oklahoma | Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli |
| DE69937272T2 (de) | 1998-01-30 | 2008-07-10 | Asubio Pharma Co., Ltd. | Verfahren zur herstellung eines peptids mittels eines hilfspeptids |
| US6242219B1 (en) | 1999-03-18 | 2001-06-05 | Xoma (Us) Llc | Methods for recombinant peptide production |
| WO2001098366A2 (en) | 2000-06-19 | 2001-12-27 | Dyax Corp. | Enterokinase cleavage sequences and their use |
| JP2002262873A (ja) | 2001-03-06 | 2002-09-17 | Inst Of Physical & Chemical Res | タンパク質ドメインの製造方法及びその方法により得られたドメインを用いるタンパク質の立体構造解析方法 |
| DK1402015T3 (da) * | 2001-06-22 | 2011-12-05 | Hoffmann La Roche | Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD |
| CN100427506C (zh) | 2001-07-26 | 2008-10-22 | 高级蛋白质技术公司 | 从融合多肽制备感兴趣的多肽的方法 |
| AU2003256365B2 (en) | 2002-07-03 | 2010-02-18 | Pfenex Inc. | Benzoate- and anthranilate-inducible promoters |
| US7390639B2 (en) | 2002-08-09 | 2008-06-24 | National Research Council Of Canada | Staphylococcal nuclease fusion proteins for the production of recombinant peptides |
| US7208585B2 (en) | 2002-09-18 | 2007-04-24 | Genencor International, Inc. | Protein purification |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| WO2004092221A1 (ja) | 2003-04-18 | 2004-10-28 | Sekisui Chemical Co. Ltd. | 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法 |
| JP2005110591A (ja) | 2003-10-08 | 2005-04-28 | Sekisui Chem Co Ltd | 蛋白質の分離方法 |
| CA2545610C (en) | 2003-11-19 | 2014-03-25 | Dow Global Technolgies Inc. | Auxotrophic pseudomonas fluorescens bacteria for recombinant protein expression |
| AU2004317306B2 (en) | 2003-11-21 | 2010-09-02 | Pelican Technology Holdings, Inc. | Improved expression systems with Sec-system secretion |
| JP2007512008A (ja) | 2003-11-24 | 2007-05-17 | ノボ ノルディスク アクティーゼルスカブ | 融合タンパク質及び該タンパク質の切断方法 |
| ES2663594T3 (es) * | 2004-01-16 | 2018-04-16 | Pfenex Inc | Expresión de proteínas de mamífero en Pseudomonas fluorescens |
| WO2006078273A2 (en) | 2004-04-26 | 2006-07-27 | The United States Of America As Represented By Teh Secretary Of Health And Human Services, Nih | Methods and compositions for producing recombinant proteins |
| JP4988337B2 (ja) | 2004-05-21 | 2012-08-01 | タカラバイオ株式会社 | ポリペプチドの製造方法 |
| US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
| ATE540981T1 (de) | 2004-08-11 | 2012-01-15 | Univ Ramot | Lösliche fusionsproteine enthaltend heterologe polypeptide |
| EP1871785B1 (en) | 2005-04-20 | 2010-05-05 | Viromed Co., Ltd | Compositions and methods for fusion protein separation |
| PL1888763T3 (pl) | 2005-06-06 | 2015-12-31 | Pfenex Inc | Systemy promotorowe indukowane mannitolem w bakteryjnych komórkach gospodarza |
| EP2021489A2 (en) | 2006-05-30 | 2009-02-11 | Dow Global Technologies Inc. | Codon optimization method |
| WO2008027099A2 (en) | 2006-05-30 | 2008-03-06 | Dow Global Technologies Inc. | Rpa optimization |
| EP1873251A1 (en) * | 2006-06-29 | 2008-01-02 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Expression vector(s) for enhanced expression of a protein of interest in eukaryotic or prokaryotic host cells |
| JP5714230B2 (ja) | 2007-01-31 | 2015-05-07 | フェネックス インコーポレイテッド | 発現上昇のための細菌リーダー配列 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| JP5444553B2 (ja) * | 2007-04-27 | 2014-03-19 | フェネックス インコーポレイテッド | 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法 |
| US8298789B2 (en) | 2007-08-09 | 2012-10-30 | Usv Limited | Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) |
| DE112008002456T5 (de) * | 2007-09-21 | 2011-01-13 | Basf Plant Science Gmbh | Pflanzen mit erhöhtem Ertrag |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| EP2127678A1 (en) | 2008-05-26 | 2009-12-02 | Roche Diagnostics GmbH | SlpA as a tool for recombinant protein and enzyme technology |
| JP2010006745A (ja) * | 2008-06-27 | 2010-01-14 | Sekisui Chem Co Ltd | 融合タンパク質、融合タンパク質固定化担体、化合物のスクリーニング方法、スクリーニング用組成物、並びに、スクリーニング用キット |
| KR101387693B1 (ko) | 2008-12-04 | 2014-04-21 | 한국생명공학연구원 | 고분비성 단백질의 스크리닝 및 재조합 단백질의 생산을 위한 융합 파트너로서 그의 용도 |
| NZ603033A (en) | 2010-04-01 | 2014-06-27 | Pfenex Inc | Methods for g-csf production in a pseudomonas host cell |
| WO2011151714A1 (en) | 2010-06-04 | 2011-12-08 | Lupin Limited | Modified sak gene for the production of recombinant proteins |
| AR086250A1 (es) | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| JP6817939B2 (ja) | 2014-12-01 | 2021-01-20 | フェネックス インク． | ペプチド産生のための融合パートナー |
| US20180023098A1 (en) | 2015-02-13 | 2018-01-25 | Sekisui Chemical Co., Ltd. | Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method |
-
2015
- 2015-11-30 JP JP2017530121A patent/JP6817939B2/ja active Active
- 2015-11-30 CN CN201580064973.4A patent/CN107532190B/zh active Active
- 2015-11-30 DK DK15866061.3T patent/DK3227455T3/da active
- 2015-11-30 ES ES15866061T patent/ES2952405T3/es active Active
- 2015-11-30 KR KR1020177017007A patent/KR102353262B1/ko active Active
- 2015-11-30 AU AU2015355242A patent/AU2015355242B2/en active Active
- 2015-11-30 NZ NZ732400A patent/NZ732400A/en unknown
- 2015-11-30 SG SG11201704362VA patent/SG11201704362VA/en unknown
- 2015-11-30 RU RU2017123283A patent/RU2017123283A/ru not_active Application Discontinuation
- 2015-11-30 WO PCT/US2015/063027 patent/WO2016089782A1/en not_active Ceased
- 2015-11-30 EP EP15866061.3A patent/EP3227455B1/en active Active
- 2015-11-30 CN CN202110725675.2A patent/CN113444183B/zh active Active
- 2015-11-30 US US14/954,766 patent/US10118956B2/en active Active
- 2015-11-30 CA CA2966358A patent/CA2966358C/en active Active
- 2015-11-30 MX MX2017006866A patent/MX386884B/es unknown
- 2015-12-01 TW TW104140109A patent/TWI702289B/zh active
- 2015-12-01 AR ARP150103916A patent/AR102865A1/es unknown
-
2018
- 2018-09-19 US US16/135,875 patent/US10981968B2/en active Active
-
2020
- 2020-09-03 JP JP2020148237A patent/JP7148579B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3227455A1 (en) | 2017-10-11 |
| BR112017011662A2 (pt) | 2018-02-27 |
| AU2015355242A1 (en) | 2017-06-22 |
| AU2015355242B2 (en) | 2020-10-08 |
| CN107532190B (zh) | 2021-07-09 |
| US10981968B2 (en) | 2021-04-20 |
| ES2952405T3 (es) | 2023-10-31 |
| DK3227455T3 (da) | 2023-08-21 |
| CN107532190A (zh) | 2018-01-02 |
| KR102353262B1 (ko) | 2022-01-18 |
| KR20170085129A (ko) | 2017-07-21 |
| JP2017536835A (ja) | 2017-12-14 |
| TW201629226A (zh) | 2016-08-16 |
| TWI702289B (zh) | 2020-08-21 |
| CN113444183B (zh) | 2025-06-17 |
| CA2966358C (en) | 2021-12-07 |
| JP2021003117A (ja) | 2021-01-14 |
| MX2017006866A (es) | 2017-11-15 |
| JP6817939B2 (ja) | 2021-01-20 |
| JP7148579B2 (ja) | 2022-10-05 |
| HK1245336A1 (en) | 2018-08-24 |
| MX386884B (es) | 2025-03-19 |
| CA2966358A1 (en) | 2016-06-09 |
| US10118956B2 (en) | 2018-11-06 |
| EP3227455B1 (en) | 2023-07-12 |
| AR102865A1 (es) | 2017-03-29 |
| EP3227455A4 (en) | 2018-07-04 |
| CN113444183A (zh) | 2021-09-28 |
| WO2016089782A1 (en) | 2016-06-09 |
| NZ732400A (en) | 2021-07-30 |
| US20190135889A1 (en) | 2019-05-09 |
| SG11201704362VA (en) | 2017-06-29 |
| US20160159877A1 (en) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017123283A (ru) | Партнеры по слиянию для получения пептидов | |
| JP2017536835A5 (https=) | ||
| US8298789B2 (en) | Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) | |
| NO20090451L (no) | Fremgangsmate for fremstilling av konjugater av insulin-lignende vekst faktor-1 og poly(etylenglukol) | |
| WO2010082804A2 (en) | Method for producing physiologically active protein or peptide using immunoglobulin fragment | |
| Su et al. | High-level expression and purification of human epidermal growth factor with SUMO fusion in Escherichia coli | |
| CA2443365A1 (en) | Methods for the recombinant production of antifusogenic peptides | |
| ES2754271T3 (es) | Polipéptidos escindibles por enteroquinasa | |
| Yang et al. | Expression and purification of the antimicrobial peptide cecropin AD by fusion with cationic elastin-like polypeptides | |
| JP2020529221A5 (https=) | ||
| CN113614113B (zh) | 含有荧光蛋白片段的融合蛋白及其用途 | |
| IL277838B1 (en) | Method for cleavage of solid phase-bound peptides from the solid phase | |
| JP2013511997A5 (https=) | ||
| CN101967493A (zh) | 一种原核表达载体及其应用 | |
| PE20020857A1 (es) | Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras | |
| US7575920B2 (en) | Yeast expression vectors for production of ITF | |
| CN103819546A (zh) | 一种以水蛭素为融合伴侣制备重组小分子蛋白或多肽的方法 | |
| CN104387473B (zh) | 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP | |
| CN110835366B (zh) | 促进蛋白质可溶性表达的标签多肽及其用途 | |
| US20200347111A1 (en) | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same | |
| RU2009115688A (ru) | Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды | |
| JP2015502167A5 (https=) | ||
| JP2015510770A (ja) | 組換えペプチドの産生方法 | |
| JP2015510770A5 (https=) | ||
| AU2024225703A1 (en) | Methods and compositions for production and purification of peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200701 |